Pfizer's (PFE) $14 billion dollar acquisition of Medivation (MDVN) is a strong purchase that might help the company 'get its groove back,' according to TheStreet's Jim Cramer. He finds it interesting that Pfizer was willing to pay more for Medivation than Sanofi (SNY) wanted to pay for the company, which shows how much Pfizer is interested in building up its oncology business. Cramer wonders if Sanofi will now be interested in adding to its stake in Regeneron (REGN) .
More from Video
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Breaking down an approach to the long side of this biotech stock.
AMSC CEO discusses that and China challenges.
One of pharma's biggest CEO's talks M&A action on the exchange.